NDC 72733-5902

Praluent

Alirocumab

Praluent is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Sanofi Us Corporation. The primary component is Alirocumab.

• Product ID: 72733-5902_03126bbf-b127-40ac-bb73-c38009793c62
• NDC: 72733-5902
• Product Type: Human Prescription Drug
• Proprietary Name: Praluent
• Generic Name: Alirocumab
• Dosage Form: Injection, Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2019-02-18
• Marketing Category: BLA / BLA
• Application Number: BLA125559
• Labeler Name: Sanofi US Corporation
• Substance Name: ALIROCUMAB
• Active Ingredient Strength: 150 mg/mL
• Pharm Classes: PCSK9 Inhibitor [EPC],PCSK9 Inhibitors [MoA],Antibodies, Monoclonal [CS]
• NDC Exclude Flag: N
• Listing Certified Through: 2020-12-31

Packaging

NDC 72733-5902-2

2 SYRINGE, GLASS in 1 CARTON (72733-5902-2) > 1 mL in 1 SYRINGE, GLASS

• Marketing Start Date: 2019-02-15
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 72733-5902-2 [72733590202]

Praluent INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA125559
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2019-02-15

Drug Details

Active Ingredients

Ingredient	Strength
ALIROCUMAB	150 mg/mL

OpenFDA Data

• SPL SET ID: a20eb852-4c25-49f0-98bc-aed493336e75
• Manufacturer:
  • Sanofi US Corporation
• UNII:
  • PP0SHH6V16
• RxNorm Concept Unique ID - RxCUI:
  • 1659161
  • 1659182
  • 1659156
  • 1659183

Pharmacological Class

• PCSK9 Inhibitor [EPC]
• PCSK9 Inhibitors [MoA]
• Antibodies
• Monoclonal [CS]

NDC Crossover Matching brand name "Praluent" or generic name "Alirocumab"

NDC	Brand Name	Generic Name
0024-5901	Praluent	alirocumab
0024-5902	Praluent	alirocumab
0024-5903	Praluent	alirocumab
0024-5904	Praluent	alirocumab
61755-020	Praluent	alirocumab
72733-5901	Praluent	Praluent
72733-5902	Praluent	Praluent
61755-021	Praluent	Praluent